Myasthenia gravis is an autoimmune disease of acquired neuromuscular junction transmission disorder mediated by autoantibodies, of which acetylcholine receptor antibodies are its most common pathogenic antibodies, and cholinesterase inhibitors are the drugs of choice for initial treatment. This evidence concerns the gene BCHE and myasthenia gravis.